CX3CL1 and neoplasm: The benefit of targeting CX3CR1–CX3CL1 is that they are the only ligand receptor to each other and inhibition of CX3CL1–CX3CR1 signaling can suppress tumor cell migration directly in case that tumor cells express CX3CR1 [296].